Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy

Clinical Cancer Research

Volumn 16, Issue 6, 2010, Pages 1834-1844

  Sikora, Andrew G ^a,b,d   Gelbard, Alexander ^a,b,c   Davies, Michael A ^a,b   Sano, Daisuke ^b   Ekmekcioglu, Suhendan ^b   Kwon, John ^b   Hailemichael, Yared ^a   Jayaraman, Padmini ^d   Myers, Jeffrey N ^b   Grimm, Elizabeth A ^b   Overwijk, Willem W ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CISPLATIN; INDUCIBLE NITRIC OXIDE SYNTHASE; N6 (1 IMINOETHYL)LYSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; IMMUNE DEFICIENCY; IN VIVO STUDY; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; CISPLATIN; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYSINE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NITRIC OXIDE SYNTHASE TYPE II; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949712411     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3123     Document Type: Article

References (43)

1. Kundu JK, Surh Y. Inflammation: gearing the journey to cancer. Mutat Res 2008;659:15-30.
2. Li L, Xu H. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol 2005;11:2539-44.
3. Vakkala M, et al. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000;6:2408-16.
4. Cianchi F, et al. Inducible Nitric Oxide Synthase Expression in Human Colorectal Cancer Correlation with Tumor Angiogenesis (ASIP); 2003.
5. Brennan PA, et al. Inducible nitric oxide synthase: correlation with extracapsular spread and enhancement of tumor cell invasion in head and neck squamous cell carcinoma. Head Neck 2008;30: 208-14.
6. Pukkila MJ, et al. Inducible nitric oxide synthase expression in pharyngeal squamous cell carcinoma: relation to p53 expression, clinicopathological data, and survival. Laryngoscope 2002;112:1084-8.
7. Albina JE, Reichner JS. Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. Cancer Metastasis Rev 1998;17: 39-53.
8. Thomas DD, et al. Heme proteins and nitric oxide (NO): the neglected, eloquent chemistry in NO redox signaling and regulation. Antioxid Redox Signal 2003;5:307-17.
9. Landar A, Darley-Usmar VM. Nitric oxide and cell signaling: modulation of redox tone and protein modification. Amino Acids 2003;25: 313-21.
10. Gow AJ, Farkouh CR, Munson DA, Posencheg MA, Ischiropoulos H. Biological significance of nitric oxide-mediated protein modifications. Am J Physiol Lung Cell Mol Physiol 2004;287:L262-8.
11. Dai Fukumura SK, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521.
12. Ekmekcioglu S, Tang C, Grimm EA. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 2005;5:103-15.
13. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide 2008;19:65-7.
14. Azad N, et al. S-nitrosylation of Bcl-2 inhibits its ubiquitin- proteasomal degradation: a novel antiapoptotic mechanism that suppresses apoptosis. J Biol Chem 2006;281:34124.
15. Mannick JB, et al. S-Nitrosylation of Mitochondrial Caspases: Rockefeller Univ Press; 2001.
16. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-16.
17. American Cancer Society (2009). Cancer Facts and Figures: 2009.
18. Massi D, et al. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 2001;194: 194-200.
19. Ekmekcioglu S, et al. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 2006;119:861-6.
20. Ekmekcioglu S, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000;6:4768-75.
21. Tang C, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 2004;279:288-98.
22. Moore WM, et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 1994;37:3886-8.
23. Xie K, et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995;181:1333-43.
24. Berkels R, Purol-Schnabel S, Roesen R. A new method to measure nitrate/nitrite with a NO-sensitive electrode. J Appl Physiol 2001;90: 317-20.
25. Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med 2007;43:645-57.
26. Seki H, et al. Differential protective action of cytokines on radiation-induced apoptosis of peripheral lymphocyte subpopulations. Cell Immunol 1995;163:30-6.
27. Tibes R, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-21.
28. Koziol JA, Maxwell DA, Fukushima M, Colmerauer ME, Pilch YH. A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment. Biometrics 1981;37:383-90.
29. Jenkins DC, et al. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 1994;70:847-9.
30. Wang G, Ji B, Wang X, Gu J. Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J Gastroenterol 2005;11:3830-3.
31. Shang Z, Li Z, Li J. In vitro effects of nitric oxide synthase inhibitor LNAME on oral squamous cell carcinoma: a preliminary study. Int J Oral Maxillofac Surg 2006;35:539-43.
32. Madhunapantula SRV, et al. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol Cancer Ther 2008;7:1297.
33. Malone JM, Saed GM, Diamond MP, Sokol RJ, Munkarah AR. The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. Am J Obstet Gynecol 2006;194:1110.
34. Engels K, et al. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res 2008;68: 5159-66.
35. Fetz V, et al. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer 2009; 124:2033-41.
36. Roy HK, et al. Inducible nitric oxide synthase (iNOS) mediates the early increase of blood supply (EIBS) in colon carcinogenesis. FEBS Lett 2007;581:3857-62.
37. Singh RP, Agarwal R. Inducible nitric oxide synthase-vascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents. Curr Cancer Drug Targets 2007;7:475-83.
38. Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 2007; 67:289-99.
39. Hatanaka T, et al. Na+- and Cl-coupled active transport of nitric oxide synthase inhibitors via amino acid transport system B(0,+). J Clin Invest 2001;107:1035-43.
40. Hansel TT, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 2003;17:1298-300.
41. Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 2003; 23:877-86.
42. Freedman BI, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999;20:493-510.
43. Karaman MW, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.